EA200000785A1 - Новые сульфонамидные производные в качестве ингибиторов рассасывания костной ткани и ингибиторов адгезии клеток - Google Patents

Новые сульфонамидные производные в качестве ингибиторов рассасывания костной ткани и ингибиторов адгезии клеток

Info

Publication number
EA200000785A1
EA200000785A1 EA200000785A EA200000785A EA200000785A1 EA 200000785 A1 EA200000785 A1 EA 200000785A1 EA 200000785 A EA200000785 A EA 200000785A EA 200000785 A EA200000785 A EA 200000785A EA 200000785 A1 EA200000785 A1 EA 200000785A1
Authority
EA
Eurasian Patent Office
Prior art keywords
inhibitors
cell adhesion
formula
compounds
bone tissue
Prior art date
Application number
EA200000785A
Other languages
English (en)
Other versions
EA003102B1 (ru
Inventor
Ануширван Пейман
Дэвид Вильям Вилл
Йохен Кнолле
Карлхайнц Шойнеманн
Дени Карниато
Жан-Франсуа Гурвест
Томас Гадек
Роберт Макдауэлл
Сара Кэтрин Бодари
Роберт Эндрю Катбертсон
Original Assignee
Авентис Фарма Дойчланд Гмбх
Генентек, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Авентис Фарма Дойчланд Гмбх, Генентек, Инк. filed Critical Авентис Фарма Дойчланд Гмбх
Publication of EA200000785A1 publication Critical patent/EA200000785A1/ru
Publication of EA003102B1 publication Critical patent/EA003102B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
    • C07D239/12—Nitrogen atoms not forming part of a nitro radical
    • C07D239/16—Nitrogen atoms not forming part of a nitro radical acylated on said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/34—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

Настоящее изобретение относится к сульфонамидным производным формулы I, в которой R, R, R, Rи Rимеют значения, указанные в формуле изобретения, их физиологически переносимым солям и их предшественникам. Соединения формулы I являются ценными фармацевтически активными соединениями. Они представляют собой антагонисты рецептора витронектина и ингибиторы адгезии клеток, а также препятствуют рассасыванию костной ткани остеокластами. В частности, они пригодны для терапии и профилактики заболеваний, по крайней мере, частично обусловленных нежелательной степенью рассасывания костной ткани, например остеопороза. Изобретение, кроме того, относится к способам получения соединений формулы I, их использованию, в частности, в качестве фармацевтически активных ингредиентов и к содержащим их фармацевтическим препаратам.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200000785A 1998-01-23 1999-01-16 Сульфонамидные производные в качестве ингибиторов рассасывания костной ткани и ингибиторов адгезии клеток, способ их получения, применение и фармацевтическая композиция EA003102B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1248998A 1998-01-23 1998-01-23
PCT/EP1999/000242 WO1999037621A1 (en) 1998-01-23 1999-01-16 Novel sulfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesion

Publications (2)

Publication Number Publication Date
EA200000785A1 true EA200000785A1 (ru) 2001-02-26
EA003102B1 EA003102B1 (ru) 2002-12-26

Family

ID=21755208

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200000785A EA003102B1 (ru) 1998-01-23 1999-01-16 Сульфонамидные производные в качестве ингибиторов рассасывания костной ткани и ингибиторов адгезии клеток, способ их получения, применение и фармацевтическая композиция

Country Status (25)

Country Link
EP (1) EP1049677A1 (ru)
JP (1) JP2002501054A (ru)
KR (1) KR20010034319A (ru)
CN (1) CN1177832C (ru)
AP (1) AP1269A (ru)
AR (1) AR014456A1 (ru)
AU (1) AU752882B2 (ru)
BG (1) BG104630A (ru)
BR (1) BR9907735A (ru)
CA (1) CA2318221A1 (ru)
EA (1) EA003102B1 (ru)
HR (1) HRP20000493A2 (ru)
HU (1) HUP0100520A3 (ru)
ID (1) ID26219A (ru)
IL (1) IL137423A0 (ru)
NO (1) NO318795B1 (ru)
NZ (1) NZ505613A (ru)
PL (1) PL341871A1 (ru)
SK (1) SK10632000A3 (ru)
TR (1) TR200002160T2 (ru)
TW (1) TWI247742B (ru)
UA (1) UA63990C2 (ru)
WO (1) WO1999037621A1 (ru)
YU (1) YU47200A (ru)
ZA (1) ZA99476B (ru)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002521450A (ja) * 1998-07-29 2002-07-16 メルク エンド カムパニー インコーポレーテッド インテグリン受容体アンタゴニスト
EP1028114A1 (en) 1999-02-13 2000-08-16 Aventis Pharma Deutschland GmbH Novel guanidine derivatives as inhibitors of cell adhesion
EP1065207A1 (en) * 1999-07-02 2001-01-03 Aventis Pharma Deutschland GmbH Naphthyridine derivatives, processes for their preparation, their use, and pharmaceutical compositions comprising them
EP1065208A1 (en) * 1999-07-02 2001-01-03 Aventis Pharma Deutschland GmbH Substituted purine derivatives as inhibitors of cell adhesion
EP1070707A1 (en) 1999-07-21 2001-01-24 Aventis Pharma Deutschland GmbH 1,4,5,6-tetrahydropyrimidine derivative as a vitronectin inhibitor
US6849639B2 (en) 1999-12-14 2005-02-01 Amgen Inc. Integrin inhibitors and their methods of use
EP1108721A1 (en) * 1999-12-15 2001-06-20 Aventis Pharma Deutschland GmbH Thienylalanine derivatives as inhibitors of cell adhesion
EP1244616A1 (en) * 1999-12-24 2002-10-02 SmithKline Beecham plc (hetero)bicyclylmethanesulfonylamino-substituted hydroxamic acid derivatives
FR2808798A1 (fr) * 2000-05-09 2001-11-16 Hoechst Marion Roussel Inc Nouveaux derives antagonistes du recepteur de la vitronectine
FR2847254B1 (fr) 2002-11-19 2005-01-28 Aventis Pharma Sa Nouveaux derives antagonistes du recepteur de la vitronectine, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les refermant
EP1727811B1 (en) * 2004-03-24 2014-11-12 Shire Orphan Therapies GmbH New compounds for the inhibition of angiogenesis and use of thereof
FR2870541B1 (fr) 2004-05-18 2006-07-14 Proskelia Sas Derives de pyrimidines antigonistes du recepteur de la vitronectine
GB0412553D0 (en) 2004-06-04 2004-07-07 Univ Aberdeen Therapeutic agents for the treatment of bone conditions
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
FR2873585B1 (fr) * 2004-07-27 2006-11-17 Aventis Pharma Sa Nouvelles formulations galeniques de principes actifs
GB0705400D0 (en) 2007-03-21 2007-05-02 Univ Aberdeen Therapeutic compounds andm their use
GB0817207D0 (en) 2008-09-19 2008-10-29 Pimco 2664 Ltd therapeutic apsac compounds and their use
GB0817208D0 (en) 2008-09-19 2008-10-29 Pimco 2664 Ltd Therapeutic apsap compounds and their use
GB201311361D0 (en) 2013-06-26 2013-08-14 Pimco 2664 Ltd Compounds and their therapeutic use
KR20160147007A (ko) 2014-05-30 2016-12-21 화이자 인코포레이티드 선택적인 안드로겐 수용체 조절제로서의 카보니트릴 유도체
EP3262028B1 (en) 2014-12-17 2021-10-27 Pimco 2664 Limited N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamide and n-(-4hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)-benzenesulfonamide compounds and their therapeutic use
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU701776B2 (en) * 1994-05-27 1999-02-04 Merck & Co., Inc. Compounds for inhibiting osteoclast-mediated bone resorption
JP3895792B2 (ja) * 1995-12-08 2007-03-22 プロスケリア・エス・ア・エス 骨形成促進剤

Also Published As

Publication number Publication date
AU752882B2 (en) 2002-10-03
KR20010034319A (ko) 2001-04-25
HUP0100520A3 (en) 2002-11-28
HUP0100520A1 (hu) 2001-07-30
TR200002160T2 (tr) 2001-07-23
IL137423A0 (en) 2001-07-24
BG104630A (en) 2001-04-30
NO20003765L (no) 2000-09-25
AU2518199A (en) 1999-08-09
YU47200A (sh) 2002-11-15
EA003102B1 (ru) 2002-12-26
WO1999037621A1 (en) 1999-07-29
BR9907735A (pt) 2000-10-17
HRP20000493A2 (en) 2001-06-30
TWI247742B (en) 2006-01-21
EP1049677A1 (en) 2000-11-08
CN1293662A (zh) 2001-05-02
CN1177832C (zh) 2004-12-01
CA2318221A1 (en) 1999-07-29
ZA99476B (en) 1999-08-05
UA63990C2 (ru) 2004-02-16
ID26219A (id) 2000-12-07
NZ505613A (en) 2002-11-26
NO20003765D0 (no) 2000-07-21
JP2002501054A (ja) 2002-01-15
PL341871A1 (en) 2001-05-07
NO318795B1 (no) 2005-05-09
AP2000001863A0 (en) 2000-09-30
AR014456A1 (es) 2001-02-28
AP1269A (en) 2004-04-03
SK10632000A3 (sk) 2001-02-12

Similar Documents

Publication Publication Date Title
EA200000785A1 (ru) Новые сульфонамидные производные в качестве ингибиторов рассасывания костной ткани и ингибиторов адгезии клеток
EA200000682A1 (ru) Новые ацилгуанидиновые производные в качестве ингибиторов резорбции костной ткани и антагонистов витронектиновых рецепторов
EA200500088A1 (ru) Трициклические модуляторы ядерного рецептора стероидного гормона
DK1140745T3 (da) Colchinolderivater som vaskulært skadelige midler
RU94041210A (ru) [/бензодиоксан, бензофуран или бензопиран/-алкиламино]-алкилзамещенные гуанидины в качестве селективных сосудосуживающих средств, способ их получения, промежуточное для них, композиция и способ ее получения
MX9204881A (es) Composicion farmaceutica que comprende moleculas activas, receptoras de calcio.
TR200100894T2 (tr) Aril ikameli propanolamin türevleri, imalat yöntemleri, ilaç maddeleri, kullanımları.
TR199701647A2 (xx) �kame edilmi� purin t�revleri,bunlar�n imalat usul�
RU2002117649A (ru) Фармацевтические композиции, содержащие золмитриптан
AU655288B2 (en) New triazolopyrimidine derivatives which are angiotensin II receptor antagonists; processes for preparing them and pharmaceutical compositions containing them
NO973652L (no) 5-(4-subst.-piperidinyl-1)-3-aryl-pentansyrederivater som tachykininreseptor-antagonist
ATE273285T1 (de) Neue guanidin-derivate als zelladhäsion- inhibitoren
DK1165544T3 (da) Substituerede 1,4-dihydroindeno[1,2-c]pyrazoler som inhibitorer af tyrosinkinase
DE69819539D1 (de) Antithrombotische mittel
UA81922C2 (ru) Низкомолекулярные органические соединения, которые увеличивают активность желатиназы в окулярных клетках
EA200200122A1 (ru) Производные нафтиридина, способ их получения, их применение и содержащие их фармацевтические композиции
EA200200121A1 (ru) Замещенные производные пурина в качестве ингибиторов клеточной адгезии
ATE286395T1 (de) Antithrombotische mittel
EA199801015A1 (ru) Производные пиперидинуксусной кислоты и их применение при лечении тромботических нарушений
WO2015050160A1 (ja) 副甲状腺ホルモンまたはその誘導体を有効成分とする筋の老化防止用医薬組成物
NO950177L (no) Farmakologisk aktive erivater
ITMI910254A1 (it) Acidi aril-o arilalchil-acil ammino-alchil-idrossidifosfonici, procedimento per la loro preparazione e loro uso in terapia osteo-articolare e dei tessuti connettori in generale
EA200301167A1 (ru) Нафтотиазиновые позитивные аллостерические модуляторы амра-рецепторов
ATE268768T1 (de) Antithrombosemittel
RU99108789A (ru) Ингибитор субэпителиального помутнения роговицы

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU